CardioComm Solutions (TSXV:EKG) EBIT: C$-0.46 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CardioComm Solutions EBIT?

CardioComm Solutions TSXV:EKG EBIT is C$-0.46 Mil as of Dec. 2025. The stock has 9 warning signs investors should review.

CardioComm Solutions's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was C$-0.18 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was C$-0.46 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CardioComm Solutions's annualized ROC % for the quarter that ended in Dec. 2025 was -84.03%. CardioComm Solutions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1,838.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. CardioComm Solutions's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -17.60%.

CardioComm Solutions  (TSXV:EKG) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CardioComm Solutions's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-0.6 * ( 1 - 0% )/( (0.774 + 0.654)/ 2 )
=-0.6/0.714
=-84.03 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.256 - 0.082 - ( 0.025 - max(0, 0.817 - 0.217+0.025))
=0.774

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.155 - 0.092 - ( 0.047 - max(0, 0.712 - 0.121+0.047))
=0.654

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

CardioComm Solutions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.708/( ( (0.039 + max(0.004, 0)) + (0.034 + max(-0.09, 0)) )/ 2 )
=-0.708/( ( 0.043 + 0.034 )/ 2 )
=-0.708/0.0385
=-1,838.96 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.141 + 0.025 + 0.018) - (0.082 + 0.098 + 0)
=0.004

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.041 + 0.01 + 0.012) - (0.092 + 0.062 + -0.0010000000000001)
=-0.09

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

CardioComm Solutions's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-0.461/2.620
=-17.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CardioComm Solutions EBIT Related Terms

CardioComm Solutions EBIT Historical Data

* Premium members only.

The historical data trend for CardioComm Solutions's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CardioComm Solutions EBIT Chart

CardioComm Solutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.02 -0.07 -0.16 -0.48

CardioComm Solutions Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.01 -0.12 -0.16 -0.18

TSXV:EKG vs VEEV, BTSG, TEM: EBIT Comparison

For the Health Information Services subindustry, CardioComm Solutions's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CardioComm Solutions EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, CardioComm Solutions's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CardioComm Solutions's EV-to-EBIT falls into.


CardioComm Solutions EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of C$-0.46 Mil mean?
CardioComm Solutions (TSXV:EKG) has a EBIT of C$-0.46 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on CardioComm Solutions.
Is CardioComm Solutions' EBIT too high?
CardioComm Solutions' current EBIT is C$-0.46 Mil.
How does CardioComm Solutions' EBIT compare to VEEV and BTSG?
CardioComm Solutions' EBIT of C$-0.46 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on CardioComm Solutions. CardioComm Solutions's current EBIT is C$-0.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CardioComm Solutions stock overvalued right now?
CardioComm Solutions (TSXV:EKG) has a current EBIT of C$-0.46 Mil. The current EBIT is C$-0.46 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For CardioComm Solutions (TSXV:EKG), the current EBIT is C$-0.46 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CardioComm Solutions Business Description

Other Exchanges EKGGF:USA
Address 110 Sheppard Avenue East, Suite 700, North York, ON, CAN, M2N 6Y8
CardioComm Solutions Inc develops software, hardware and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets globally. The Company has one operating segment, which involves the development of software and the sale of ECG recording equipment and ECG reading services for the cardiology field. Substantially all the Company's operations, assets, and employees are in Canada. Revenue is earned in Canada and the United States. Its products are GEMS Sirona, GEMS WIN, Trident Pro 40L, HeartCheck CardiBeat - Mobile ECG Device, HeartCheck SMART Monitoring, and Others.